Table 2.
Median MPR of essential medicines in Nanjing from 2016 to 2020.
| Year | Median of MPR for LPGs (37) | Median of MPR for OBs (17) | P | ||
|---|---|---|---|---|---|
| MPR (IQR) | Median change in MPR (IQR) | MPR (IQR) | Median change in MPR (IQR) | ||
| 2016 | 1.20 (2.86) | - | 10.41 (10.65) | - | 0.000 |
| 2017 | 1.29 (2.65) | −0.04 (0.33) | 9.88 (10.05) | −0.53 (0.60)** | 0.000 |
| 2018 | 2.22 (2.84) | −0.01 (0.45) | 9.29 (10.13) | −0.69 (0.83)** | 0.000 |
| 2019 | 2.53 (5.12) | 0.16 (1.17)** | 9.07 (9.89) | −0.28 (0.29)** | 0.001 |
| 2020 | 1.39 (2.12) | −0.19 (1.30)** | 7.63 (9.71) | −0.22 (0.93)** | 0.000 |
P-value reported in the table is used to reflect the difference of median MPR between LPGs and OBs; IQR, interquartile range; Median change in MPR, the median of MPR change of each medicine surveyed between adjacent years; LPGs, lowest-price generics; OBs, originator brands.
**
p < 0.01.